Skip to content

News & updates

Media Coverage

How MiRXES scaled from cancer to COVID-19: manufacturing more than 500K COVID-19 tests a week
Biotech firms race against time to get around logistical challenges
MiRXES leading the way in microRNA technology
Home-grown firms linked to pandemic work will continue to attract demand, investments
MiRXES’ role in Singapore’s pivot to mass COVID-19 tests
MiRXES is 102nd on Financial Times ranking of Asia-Pacific High Growth Companies
COVID-19 putting MiRXES and Singapore on global deeptech radar
MiRXES heeding the call for COVID-19 testing
MiRXES and Singapore scientists on the front lines of fight against COVID-19
MiRXES — A game changer in microRNA applications
Singapore clears Fortitude Kit SARS-CoV-2 test for clinical use
MiRXES to mass-produce Singapore-developed Fortitude Kit SARS-CoV-2 test kits
MiRXES named Singapore’s fastest growing company in the health sector from 2015-2018
Timely guidance for MiRXES from Pro-Enterprise Panel
GASTROClear blood test for stomach cancer first step to ending all cancer deaths
MiRXES has a real shot at stamping out cancer deaths
Seniors tested for stomach cancer with GASTROClear at free screening in Teck Ghee
MiRXES’ holding company raises US$40M to expand its non-invasive cancer detection technologies in Asia
MiRXES’ holding company clinches $55.03m funding
MiRXES team gets funding to ‘eliminate late-stage cancer’
MiRXES’ holding company launched with US$40m Series A funding
Promising biomedical start-ups in Singapore – MiRXES
MiRXES co-founder Zhou Lihan’s entrepreneurial journey
MiRXES collaborates with Johnson & Johnson to develop miRNA test for lung cancer
MiRXES aims to make cancer tests more accessible
Venturecraft invests in MiRXES
MiRXES creates alternative test for cancer
Screening for early stage stomach cancer with a blood test
Singapore scientists develop blood test to spot stomach cancer